AcquisitionAug 3, 2026Pending
🇺🇸 United States
LLantheus Holdings, Inc.CUCurium US Holdings LLC
Healthcare › Life Science Tools & Diagnostics
Deal valueUndisclosed
AnnouncedAug 3, 2026
ConsiderationCash
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentYes
Overview
Curium US Holdings LLC agreed to acquire Lantheus via merger for $102.50 per share in cash plus CVRs of up to $12.00 per share, for a total transaction value of up to about $8.0 billion.
Deal rationale
The combination joins Curium's theranostics portfolio and global manufacturing platform with Lantheus' complementary U.S. radiodiagnostics business to span the full nuclear medicine value chain.
AI-generated from the SEC filingPendingHealthcare › Life Science Tools & DiagnosticsUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Cash |
Advisors
Buy-side
JJefferiesJPJ.P. MorganPPPJT Partners
Sell-side
BOBank of AmericaMSMorgan StanleySPSolomon Partners
Parties
Acquirer
CUCurium US Holdings LLC
- Headquarters
- United States
- Ticker
- —